Innoviva Company Profile (NASDAQ:INVA)

About Innoviva

Innoviva logoInnoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Its portfolio focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). It operates in providing capital return to stockholders by maximizing the potential value of its respiratory assets partnered with GSK segment. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of VI, a LABA and FF, an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a LABA for the treatment of chronic obstructive pulmonary diseases (COPD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: INVA
  • CUSIP: 88338T10
Key Metrics:
  • Previous Close: $12.01
  • 50 Day Moving Average: $11.07
  • 200 Day Moving Average: $11.01
  • 52-Week Range: $107,639,000.00 - $8.67
  • Trailing P/E Ratio: 22.72
  • Foreward P/E Ratio: 8.42
  • P/E Growth: 0.13
  • Market Cap: $1.30B
  • Outstanding Shares: 107,639,000
  • Beta: 2.33
Profitability:
  • Net Margins: 44.57%
  • Return on Equity: -20.31%
  • Return on Assets: 19.38%
Debt:
  • Debt-to-Equity Ratio: -2.03%
  • Current Ratio: 17.36%
  • Quick Ratio: 12.47%
Additional Links:
Companies Related to Innoviva:

Analyst Ratings

Consensus Ratings for Innoviva (NASDAQ:INVA) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $13.00 (7.97% upside)

Analysts' Ratings History for Innoviva (NASDAQ:INVA)
Show:
DateFirmActionRatingPrice TargetDetails
10/31/2016Cowen and CompanyUpgradeMarket Perform -> Outperform$15.00View Rating Details
7/31/2016Robert W. BairdReiterated RatingNeutral$9.00 -> $11.00View Rating Details
10/5/2015Morgan StanleyReiterated RatingOverweight$7.00 -> $9.00View Rating Details
9/10/2015Sanford C. BernsteinReiterated RatingMarket Perform$15.00View Rating Details
9/9/2015Bank of America CorporationDowngradeBuy -> Neutral$16.00 -> $13.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Innoviva (NASDAQ:INVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017        
2/9/2017Q4 2016$0.19$0.22$40.72 million$43.60 millionViewListenView Earnings Details
10/27/2016Q316$0.19$0.17$38.71 million$33.30 millionViewListenView Earnings Details
7/28/2016Q216$0.11$0.17$31.13 million$32.47 millionViewListenView Earnings Details
4/28/2016Q116$0.09$0.04$28.61 million$24.17 millionViewListenView Earnings Details
2/3/2016Q415$0.01$0.04$20.17 million$22.80 millionViewN/AView Earnings Details
10/28/2015Q315($0.03)($0.04)$15.23 million$13.56 millionViewListenView Earnings Details
7/29/2015Q2($0.06)($0.07)$10.90 million$10.70 millionViewListenView Earnings Details
5/6/2015Q115($0.08)($0.09)$6.80 millionViewListenView Earnings Details
2/18/2015Q414($0.15)($0.14)$5.42 million$7.30 millionViewN/AView Earnings Details
10/30/2014Q314($0.14)($0.19)$6.30 millionViewN/AView Earnings Details
8/18/2014($0.53)($0.18)ViewN/AView Earnings Details
8/6/2014Q214($0.44)($0.57)$4.39 million$0.93 millionViewN/AView Earnings Details
5/6/2014Q114($0.53)($0.62)$4.52 million$0.17 millionViewN/AView Earnings Details
2/6/2014Q413($0.38)($0.46)$6.03 million$1.60 millionViewN/AView Earnings Details
10/24/2013Q313$0.69($0.44)$3.08 million$0.44 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.46)($0.37)$1.43 million$1.33 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.38)($0.39)$2.71 million$1.34 millionViewN/AView Earnings Details
2/12/2013Q4 2012($0.36)($0.33)$3.88 million$5.80 millionViewN/AView Earnings Details
10/30/2012($0.39)($0.37)ViewN/AView Earnings Details
7/31/2012($0.42)($0.42)ViewN/AView Earnings Details
4/26/2012$1.02$0.93ViewN/AView Earnings Details
2/9/2012($0.38)($0.45)ViewN/AView Earnings Details
10/27/2011($0.33)($0.37)ViewN/AView Earnings Details
7/28/2011($0.27)($0.31)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Innoviva (NASDAQ:INVA)
Current Year EPS Consensus Estimate: $1.29 EPS
Next Year EPS Consensus Estimate: $1.43 EPS

Dividends

Dividend History for Innoviva (NASDAQ:INVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2015quarterly$0.257.01%9/8/20159/10/20159/30/2015
5/7/2015quarterly$0.256.43%6/10/20156/12/20156/30/2015
2/24/2015quarterly$0.255.85%3/10/20153/12/20153/31/2015
10/31/2014quarterly$0.256.24%11/21/201411/25/201412/23/2014
8/6/2014quarterly$0.258/26/20148/28/20149/18/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Innoviva (NASDAQ:INVA)
Insider Ownership Percentage: 1.60%
Institutional Ownership Percentage: 77.62%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/22/2016Theodore L Witek JrVPSell3,700$10.84$40,108.00View SEC Filing  
11/21/2016Eric DesparbesCFOSell1,800$10.89$19,602.00View SEC Filing  
8/22/2016Eric DesparbesCFOSell3,700$11.77$43,549.00View SEC Filing  
5/18/2016James L TyreeDirectorSell813$10.47$8,512.11View SEC Filing  
5/11/2015Plc GlaxosmithklineMajor ShareholderBuy85,579$1,369,260.00$117,179,901,540.00View SEC Filing  
8/13/2014Junning LeeVPSell53,424$22.50$1,202,040.00View SEC Filing  
8/12/2014Bradford J ShaferSVPSell28,156$22.13$623,092.28View SEC Filing  
8/11/2014Bradford J ShaferSVPSell27,108$22.12$599,628.96View SEC Filing  
9/12/2013Rick WinninghamCEOSell22,353$40.03$894,790.59View SEC Filing  
7/30/2013Mathai MammenSVPSell7,000$36.51$255,570.00View SEC Filing  
6/7/2013Bradford J ShaferSVPSell31,038$35.04$1,087,571.52View SEC Filing  
5/29/2013David L BrinkleyInsiderSell3,808$35.01$133,318.08View SEC Filing  
5/13/2013David L BrinkleyInsiderSell16,129$40.33$650,482.57View SEC Filing  
8/7/2012Michael W AguiarCFOSell60,000$27.04$1,622,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Innoviva (NASDAQ:INVA)
DateHeadline
finance.yahoo.com logoCan The Uptrend Continue for Innoviva (INVA)? (NASDAQ:INVA)
finance.yahoo.com - February 16 at 4:49 PM
News IconLookout for these Two stocks: Innoviva, Inc. (NASDAQ:INVA), VWR Corporation (NASDAQ:VWR) - The Newburgh Press (NASDAQ:INVA)
newburghpress.com - February 16 at 8:09 AM
News IconSell-side is Weighing in on Innoviva Inc (NYSE:INVA) Earnings - Aiken Advocate (NASDAQ:INVA)
aikenadvocate.com - February 15 at 9:07 PM
capitalcube.com logoInnoviva, Inc. :INVA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 14, 2017 (NASDAQ:INVA)
www.capitalcube.com - February 14 at 7:18 PM
News IconNews Review: Quotient Technology Inc. (NYSE:QUOT), Innoviva, Inc. (NASDAQ:INVA) - The Newburgh Press (NASDAQ:INVA)
newburghpress.com - February 13 at 7:00 PM
capitalcube.com logoInnoviva, Inc. :INVA-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017 (NASDAQ:INVA)
www.capitalcube.com - February 13 at 6:59 PM
seekingalpha.com logoInnoviva: Strong Upside As Fears Subside - Seeking Alpha (NASDAQ:INVA)
seekingalpha.com - February 12 at 4:33 AM
finance.yahoo.com logoEdited Transcript of INVA earnings conference call or presentation 9-Feb-17 10:00pm GMT (NASDAQ:INVA)
finance.yahoo.com - February 10 at 6:42 PM
News IconInnoviva Inc INVA Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:INVA)
www.bioportfolio.com - February 10 at 4:54 AM
businesswire.com logoInnoviva Reports Fourth Quarter and Full Year 2016 Financial Results - Business Wire (press release) (NASDAQ:INVA)
www.businesswire.com - February 9 at 11:53 PM
nasdaq.com logoInnoviva (INVA) Shares Cross Above 200 DMA (NASDAQ:INVA)
www.nasdaq.com - February 9 at 6:52 PM
biz.yahoo.com logoQ4 2016 Innoviva Inc Earnings Release - After Market Close (NASDAQ:INVA)
us.rd.yahoo.com - February 9 at 6:52 PM
us.rd.yahoo.com logoInnoviva Reports Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:INVA)
us.rd.yahoo.com - February 9 at 6:52 PM
biz.yahoo.com logoINNOVIVA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Amendments to Articles of Inc. or B (NASDAQ:INVA)
us.rd.yahoo.com - February 9 at 6:52 PM
sg.finance.yahoo.com logoInnoviva beats 4Q profit forecasts (NASDAQ:INVA)
sg.finance.yahoo.com - February 9 at 6:52 PM
News IconInvestor Update on Shares of Innoviva, Inc. (NASDAQ:INVA) - Midway Monitor (NASDAQ:INVA)
midwaymonitor.com - February 8 at 11:42 PM
News IconInnoviva, Inc. Company Profile (NASDAQ:INVA)
www.bioportfolio.com - February 2 at 6:39 PM
finance.yahoo.com logoInnoviva to Report Fourth Quarter and Full Year 2016 Financial Results on February 9, 2017 at 5:00 p.m. EST (NASDAQ:INVA)
finance.yahoo.com - February 2 at 6:38 PM
thestreet.com logoInteresting INVA Put And Call Options For September 15th (NASDAQ:INVA)
www.thestreet.com - January 31 at 11:43 PM
News IconShares in Focus: Innoviva, Inc. (NASDAQ:INVA) - The Tribune (NASDAQ:INVA)
lakecitytribune.com - January 31 at 6:42 PM
News IconStock Survey: Viewing Levels for Innoviva, Inc. (NASDAQ:INVA) - The Tribune (NASDAQ:INVA)
lakecitytribune.com - January 29 at 11:11 PM
News IconVC Score In Focus for Innoviva, Inc. (NASDAQ:INVA) - The Tribune (NASDAQ:INVA)
lakecitytribune.com - January 28 at 11:06 PM
News IconInvestor Monitor: Narrowing in on Innoviva, Inc. (NASDAQ:INVA) - The Tribune (NASDAQ:INVA)
lakecitytribune.com - January 28 at 5:56 AM
capitalcube.com logoInnoviva, Inc. breached its 50 day moving average in a Bearish Manner : INVA-US : January 19, 2017 (NASDAQ:INVA)
www.capitalcube.com - January 19 at 7:44 PM
News IconAnalysts Take the Wheel on Innoviva Inc (NYSE:INVA) Shares and Where They Might Be Headed - Aiken Advocate (NASDAQ:INVA)
aikenadvocate.com - January 18 at 11:28 PM
bizjournals.com logoHow These Application Software Stocks are Faring? -- Innoviva, Proofpoint, Manhattan Associates, and NQ Mobile (NASDAQ:INVA)
www.bizjournals.com - January 12 at 6:25 PM
finance.yahoo.com logoEhave, Inc. Appoints New Members to its Board of Directors (NASDAQ:INVA)
finance.yahoo.com - January 10 at 6:52 PM
News IconFollowing the Numbers for Innoviva, Inc. (NASDAQ:INVA) - Wall Street Beacon (NASDAQ:INVA)
wsbeacon.com - January 8 at 5:42 PM
nasdaq.com logoINVA Makes Bullish Cross Above Critical Moving Average (NASDAQ:INVA)
www.nasdaq.com - January 4 at 6:50 PM
News IconEquity Check-in on Shares of Innoviva, Inc. (NASDAQ:INVA) - Wall Street Beacon (NASDAQ:INVA)
wsbeacon.com - December 30 at 11:22 PM
capitalcube.com logoInnoviva, Inc. – Value Analysis (NASDAQ:INVA) : December 29, 2016 (NASDAQ:INVA)
www.capitalcube.com - December 29 at 5:59 PM
capitalcube.com logoInnoviva, Inc. breached its 50 day moving average in a Bearish Manner : INVA-US : December 28, 2016 (NASDAQ:INVA)
www.capitalcube.com - December 28 at 10:50 AM
News IconInvestor Update: Checking on Shares of Innoviva, Inc. (NASDAQ:INVA) - Wall Street Beacon (NASDAQ:INVA)
wsbeacon.com - December 27 at 10:54 AM
News IconEquity in Focus: Innoviva, Inc. (NASDAQ:INVA) - Wall Street Beacon (NASDAQ:INVA)
wsbeacon.com - December 26 at 10:37 AM
News IconMarket Scope: F-Score and Volatility Review for Innoviva, Inc. (NASDAQ:INVA) - The Business Journal (NASDAQ:INVA)
belmontbusinessjournal.com - December 21 at 8:58 AM
News IconInvestor Watch: Narrowing in on Innoviva, Inc. (NASDAQ:INVA) - Business Daily Leader (NASDAQ:INVA)
businessdailyleader.com - December 21 at 8:58 AM
streetinsider.com logoGlaxoSmithKline (GSK), Innoviva (INVA) Initiate Phase III Study of FF/UMEC/VI Combo in Patients with Asthma - StreetInsider.com (NASDAQ:INVA)
www.streetinsider.com - December 21 at 8:58 AM
feeds.reuters.com logoBRIEF-Theravance biopharma highlights initiation of Phase 3 study (NASDAQ:INVA)
feeds.reuters.com - December 19 at 6:25 PM
rttnews.com logoGlaxo Begins Phase III Study Of Triple Combination Therapy In Asthma Patients (NASDAQ:INVA)
www.rttnews.com - December 19 at 11:34 AM
News IconGlaxoSmithKline, Innoviva Start Phase III Study for Triple Combination Asthma Therapy (NASDAQ:INVA)
ih.advfn.com - December 19 at 11:33 AM
streetinsider.com logoGlaxoSmithKline (GSK), Innoviva (INVA) Initiate Phase III Study of FF/UMEC/VI Combo in Patients with Asthma (NASDAQ:INVA)
www.streetinsider.com - December 19 at 11:33 AM
4-traders.com logoInnoviva : GSK starts phase III study of once-daily closed triple combination therapy FF/UMEC/VI in patients with asthma | GSK (NASDAQ:INVA)
www.4-traders.com - December 19 at 11:33 AM
uk.finance.yahoo.com logoGSK Starts Phase III Study of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI in Patients with Asthma (NASDAQ:INVA)
us.rd.yahoo.com - December 19 at 11:33 AM
News IconInvestor Update: Looking at Shares of Innoviva, Inc. (NASDAQ:INVA) - Liberty News (NASDAQ:INVA)
libertynewsrecord.com - December 18 at 6:00 PM
News IconMF Rank Review for Innoviva, Inc. (NASDAQ:INVA) - OIB News (NASDAQ:INVA)
oibnews.com - December 18 at 6:00 PM
News IconChecking the Levels for Innoviva, Inc. (NASDAQ:INVA) - Business Daily Leader (NASDAQ:INVA)
businessdailyleader.com - December 16 at 6:31 PM
News IconF-Score in Focus for Innoviva, Inc. (NASDAQ:INVA) - The Business Journal (NASDAQ:INVA)
belmontbusinessjournal.com - December 15 at 11:38 PM
News IconChecking ROIC Numbers for Innoviva, Inc. (NASDAQ:INVA) - Wall Street Beacon (NASDAQ:INVA)
wsbeacon.com - December 15 at 11:38 PM
News IconCompany in Focus: Innoviva, Inc. (NASDAQ:INVA) - Business Daily Leader (NASDAQ:INVA)
businessdailyleader.com - December 13 at 10:20 AM
News IconStock Watch on Shares of Innoviva, Inc. (NASDAQ:INVA) - OIB News (NASDAQ:INVA)
oibnews.com - December 9 at 6:00 PM

Social

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Where is Innoviva's stock going? Where will Innoviva's stock price be in 2017?

2 brokerages have issued 1-year target prices for Innoviva's stock. Their predictions range from $11.00 to $15.00. On average, they expect Innoviva's stock price to reach $13.00 in the next twelve months.

When will Innoviva announce their earnings?

Innoviva is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

Who owns Innoviva stock?

Innoviva's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (13.60%), Iridian Asset Management LLC CT (7.01%), Sarissa Capital Management LP (2.74%), State Street Corp (1.94%), GLG LLC (0.75%) and Guggenheim Capital LLC (0.25%). Company insiders that own Innoviva stock include Eric Desparbes, James L Tyree, Plc Glaxosmithkline and Theodore L Witek Jr.

Who sold Innoviva stock? Who is selling Innoviva stock?

Innoviva's stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, FMR LLC, Tudor Investment Corp Et Al, Pacad Investment Ltd., Federated Investors Inc. PA, Allianz Asset Management AG, Old West Investment Management LLC and TCW Group Inc.. Company insiders that have sold Innoviva stock in the last year include Eric Desparbes, James L Tyree and Theodore L Witek Jr.

Who bought Innoviva stock? Who is buying Innoviva stock?

Innoviva's stock was acquired by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, GLG LLC, State Street Corp, Guggenheim Capital LLC, Comerica Bank, Public Sector Pension Investment Board, Dimensional Fund Advisors LP and Thrivent Financial for Lutherans.

How do I buy Innoviva stock?

Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Innoviva stock cost?

One share of Innoviva stock can currently be purchased for approximately $12.04.

Innoviva (NASDAQ:INVA) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Earnings History Chart

Earnings by Quarter for Innoviva (NASDAQ:INVA)

Dividend History Chart

Dividend Payments by Quarter for Innoviva (NASDAQ:INVA)

Last Updated on 2/19/2017 by MarketBeat.com Staff